Table 5 Baseline characteristics and effectiveness and safety outcomes between different anti-CGRP mAbs
Erenumab | Galcanezumab | Fremanezumab | p | |
|---|---|---|---|---|
n | 38 | 85 | 39 | |
Baseline differences | ||||
Age [mean ± SD] | 69.8 ± 5.0 | 69.8 ± 4.4 | 68.8 ± 3.7 | 0.485 |
Proportion of chronic migraine [n (%)] | 29 (76.3) | 70 (82.4) | 32 (82.1) | 0.721 |
MMD [mean ± SD] | 19.5 ± 7.9 | 17.6 ± 7.2 | 17.2 ± 7.7 | 0.365 |
MHD [mean ± SD] | 22.8 ± 7.1 | 22.7 ± 7.1 | 24.9 ± 6.1 | 0.228 |
Medication overuse [n (%)] | 27 (71.1) | 56 (65.9) | 24 (63.2) | 0.760 |
MIDAS [mean ± SD] | 73.3 ± 66 n = 33/38 | 89.5 ± 79 n = 68/85 | 66.2 ± 54.7 n = 28/39 | 0.284 |
Concomitant onabotulinum toxin A [n (%)] | 5 (13.2) | 20 (23.5) | 6 (15.4) | 0.322 |
Primary endpoints | ||||
MMD reduction at M6 [mean ± SD] | -9.9 ± 8.2 n = 34/38 | -10.4 ± 7.3 n = 66/85 | -9.6 ± 6.5 n = 34/39 | 0.890 |
Total adverse effects [n (%)] | 15 (39.5) | 23 (27.1) | 3 (7.7) | 0.005 |